Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases.

Fecha de publicación: 05/01/2024 Fecha Ahead of Print: 05/01/2024

Autores de IIS La Fe

Elvira Mora Castera

Autor

Participantes ajenos a IIS La Fe

Del Pozo V
Bobolea I
Rial MJ
Espigol-Frigolé G
Solans Laqué R
Hernández-Rivas JM
Crespo-Lessmann A
Izquierdo Alonso JL
Domínguez Sosa MS
Maza-Solano J
Atienza-Mateo B
Bañas-Conejero D
Moure AL
Rúa-Figueroa Í

Grupos

Hematología y Hemoterapia

Abstract

Eosinophil-related diseases represent a group of pathologic conditions with highly heterogeneous clinical presentation and symptoms ranging from mild to critical. Both systemic and localized forms of disease are typically treated with glucocorticoids. The approval of novel biologic therapies targeting the interleukin-5 pathway can help reduce the use of systemic glucocorticoids (SGC) in eosinophilic diseases and reduce the risk of SGC-related adverse effects (AEs). In this article, a panel of experts from different medical specialties reviewed current evidence on the use of SGC in two systemic eosinophilic diseases: Eosinophilic Granulomatosis with PolyAngiitis (EGPA) and HyperEosinophilic Syndrome (HES); and in two single-organ (respiratory) eosinophilic diseases: Chronic RhinoSinusitis with Nasal Polyps (CRSwNP) and Severe Asthma with Eosinophil Phenotype (SA-EP), and contrasted it with their experience in clinical practice. Using nominal group technique, they reached consensus on key aspects related to the dose and tapering of SGC as well as on the initiation of biologics as SGC-sparing agents. Early treatment with biologics could help prevent AEs associated with medium and long-term use of SGC.

Copyright © 2024 del Pozo, Bobolea, Rial, Espigol-Frigolé, Solans Laqué, Hernández-Rivas, Mora, Crespo-Lessmann, Izquierdo Alonso, Domínguez Sosa, Maza-Solano, Atienza-Mateo, Bañas-Conejero, Moure and Rúa-Figueroa.

Datos de la publicación

ISSN/ISSNe:: 1664-3224, 1664-3224
Tipo:: Article
Páginas:: 1310211-1310211
DOI:: 10.3389/fimmu.2023.1310211
PubMed:: 38250075
Factor de Impacto:: 2,331 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Del Pozo V:: Immunology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain
Bobolea I:: Allergy Department, Severe Asthma Unit, Hospital Clínic Barcelona, Barcelona, Spain
Rial MJ:: Allergy Department, Severe Asthma Unit, Complexo Hospitalario Universitario A Coruña, A Coruña, Spain

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), A Coruña, Spain
Espigol-Frigolé G:: Department of Autoimmune Diseases, Hospital Clinic Clínic, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Solans Laqué R:: Autoimmune Systemic Diseases Unit, Internal Medicine Department, Vall d'Hebron Hospital, Autonomous University of Barcelona, Barcelona, Spain
Hernández-Rivas JM:: Department of Medicine, University of Salamanca & Servicio de Hematología, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain
Mora E:: Hematology Department, La Fe University and Polytechnic Hospital, La Fe Research Institute, Valencia, Spain
Crespo-Lessmann A:: Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
Izquierdo Alonso JL:: Department of Medicine and Medical Specialties, University of Alcalá, Alcalá de Henares, Madrid, Spain

Pulmonology Service, Guadalajara University Hospital, Guadalajara, Spain
Domínguez Sosa MS:: Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, University Hospital of Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain
Maza-Solano J:: Rhinology Unit, Department of Otolaryngology, Head and Neck Surgery, Virgen Macarena University Hospital, Sevilla, Spain
Atienza-Mateo B:: Division of Rheumatology, University Hospital of Marqués de Valdecilla, Instituto de Investigación Marqués de Valdecilla (IDIVAL), Immunopathology group, Santander, Spain
Bañas-Conejero D:: Specialty Care Medical Department, GSK, Madrid, Spain
Moure AL:: Specialty Care Medical Department, GSK, Madrid, Spain
Rúa-Figueroa Í:: Rheumatology Department, University Hospital of Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

Keywords

adverse events; biologics; eosinophilic diseases; systemic glucocorticoids; tapering; treatment optimisation

Cita

Cita Bibliográfica